We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

29 hedge funds and large institutions have $3.19M invested in AYTU BioPharma in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

21% more funds holding

Funds holding: 24 → 29 (+5)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

2.72% less ownership

Funds ownership: 33.31% → 30.58% (-2.7%)

34% less capital invested

Capital invested by funds: $4.81M → $3.19M (-$1.62M)

Holders
29
Holders Change
+5
Holders Change %
+20.83%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
5
Reduced
5
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$21.4K
2
Citadel Advisors
Citadel Advisors
Florida
+$20.2K
3
Millennium Management
Millennium Management
New York
+$18.9K
4
MCM
MAI Capital Management
Ohio
+$6.53K
5
UBS Group
UBS Group
Switzerland
+$2.26K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$171K
2
AC
Armistice Capital
New York
-$157K
3
Northern Trust
Northern Trust
Illinois
-$34.2K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$19.9K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$4.33K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$1.85M – – –
SCM
2
Stonepine Capital Management
Oregon
$693K -$171K -93,409 -19%
AC
3
Armistice Capital
New York
$255K -$157K -86,000 -36%
Renaissance Technologies
4
Renaissance Technologies
New York
$128K +$1.28K +700 +0.9%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$71.4K -$4.33K -2,369 -5%
Vanguard Group
6
Vanguard Group
Pennsylvania
$46.6K – – –
BlackRock
7
BlackRock
New York
$38.7K – – –
Acadian Asset Management
8
Acadian Asset Management
Massachusetts
$24K – – –
TSS
9
Two Sigma Securities
New York
$19.9K +$21.4K +11,690 New
Citadel Advisors
10
Citadel Advisors
Florida
$18.5K +$20.2K +11,062 New
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$18.2K -$19.9K -10,906 -50%
Millennium Management
12
Millennium Management
New York
$17.3K +$18.9K +10,369 New
MCM
13
MAI Capital Management
Ohio
$6.08K +$6.53K +3,575 New
TRCT
14
Tower Research Capital (TRC)
New York
$4.46K +$2.1K +1,149 +78%
UBS Group
15
UBS Group
Switzerland
$2.54K +$2.26K +1,236 +475%
Osaic Holdings
16
Osaic Holdings
Arizona
$510 – – –
Morgan Stanley
17
Morgan Stanley
New York
$493 – – –
Wells Fargo
18
Wells Fargo
California
$210 – – –
Bank of America
19
Bank of America
North Carolina
$170 +$4 +2 +2%
CIBC Private Wealth Group
20
CIBC Private Wealth Group
Georgia
$148 – – –
JP Morgan Chase
21
JP Morgan Chase
New York
$125 -$435 -238 -76%
SS
22
SBI Securities
Japan
$104 +$111 +61 New
US Bancorp
23
US Bancorp
Minnesota
$97 +$99 +54 +1,800%
Group One Trading
24
Group One Trading
Illinois
$62 – – –
BNP Paribas Financial Markets
25
BNP Paribas Financial Markets
France
$39 +$42 +23 New
1
2

AYTU Hedge Fund Activity: Q4 2024 in Review

29 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q4 2024, worth a combined $3.19M — down 34% from $4.81M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AYTU positions and 2 closed out — a net gain of 5 holders — while 5 added to existing stakes and 5 trimmed.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $21.4K. The largest seller was Stonepine Capital Management, cutting an estimated $171K.

  • 29 institutional investors held AYTU BioPharma (AYTU) as of Q4 2024, up from 24 in Q3 2024.
  • Funds reported $3.19M of AYTU BioPharma stock for Q4 2024, down 34% quarter-over-quarter.
  • 7 funds opened new AYTU BioPharma positions in Q4 2024 and 2 closed out, a net change of +5 holders.
  • The largest AYTU BioPharma buyer in Q4 2024 was Two Sigma Securities, an estimated $21.4K added.
  • The largest AYTU BioPharma seller in Q4 2024 was Stonepine Capital Management, an estimated $171K sold.

Based on aggregated 13F filings for Q4 2024.